Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Published:2016-07 Issue:7 Volume:17 Page:976-983
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Goldberg Sarah B,Gettinger Scott N,Mahajan Amit,Chiang Anne C,Herbst Roy S,Sznol Mario,Tsiouris Apostolos John,Cohen Justine,Vortmeyer Alexander,Jilaveanu Lucia,Yu James,Hegde Upendra,Speaker Stephanie,Madura Matthew,Ralabate Amanda,Rivera Angel,Rowen Elin,Gerrish Heather,Yao Xiaopan,Chiang Veronica,Kluger Harriet M

Funder

Merck and the Yale Cancer Center

NIH

Yale SPORE in Skin Cancer

National Center for Research Resources

National Center for Advancing Translational Science

National Institutes of Health (NIH)

Lung Cancer research Foundation

LUNGevity and Melanoma Research Alliance

Yale SPORE in Lung Cancer

Office of the Secretary of Defense

Publisher